Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia

Alexandros Rouvas1 2nd Department of Ophthalmology, Medical School of Athens University, Athens, Greece

Panagiotis Malamos2 Department of Ophthalmology, NHS, “G Gennimatas” General Hospital, Athens, GreeceCorrespondence[email protected]

Maria Douvali1 2nd Department of Ophthalmology, Medical School of Athens University, Athens, Greece

Amalia Ntouraki1 2nd Department of Ophthalmology, Medical School of Athens University, Athens, Greece

Nikos N Markomichelakis1 2nd Department of Ophthalmology, Medical School of Athens University, Athens, Greece

Pages 1357-1362 | Published online: 05 Jul 2013

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

GassJDA fluorescein angiographic study of macular dysfunction secondary to retinal vascular disease. V. Retinal telangiectasisArch Ophthalmol19688055926055684308
PubMedGoogle Scholar
GassJDOyakawaRTIdiopathic juxtafoveolar retinal telangiectasisArch Ophthalmol198210057697807082207
PubMedGoogle Scholar
YannuzziLABardalAMFreundKBChenKJEandiCMBlodiBIdiopathic macular telangiectasiaArch Ophthalmol2006124445046016606869
PubMedGoogle Scholar
ParkDWSchatzHMcDonaldHRJohnsonRNGrid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasisOphthalmology199710411183818469373114
PubMed Web of Science ®Google Scholar
De LahitteGDCohenSYGaudricALack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularizationAm J Ophthalmol2004138589289415531343
PubMed Web of Science ®Google Scholar
WuLEvansTArévaloJFLong-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasiaRetina200828231431918301037
PubMed Web of Science ®Google Scholar
GragoudasESAdamisAPCunninghamETJrFeinsodMGuyerDRfor VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degenerationN Engl J Med2004351272805281615625332
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
AveryRLPearlmanJPieramiciDJIntravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathyOphthalmology2006113101695170517011951
PubMed Web of Science ®Google Scholar
KriechbaumKMichelsSPragerFIntravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective studyBr J Ophthalmol200892451852218211942
PubMed Web of Science ®Google Scholar
AdamisAPShimaDTThe role of vascular endothelial growth factor in ocular health and diseaseRetina200525211111815689799
PubMed Web of Science ®Google Scholar
ChewEYParafoveal telangiectasisRyanSJHintonDRSchachatAPWilkinsonCPRetina4th edSt LouisMosby2006214091415
Google Scholar
Charbel IssaPFingerRPHolzFGSchollHPEighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasiaBr J Ophthalmol200892794194518577646
PubMed Web of Science ®Google Scholar
ViannaRNSqueriGTurquettiRBrasilOFBurnierMNJrIntravitreal pegaptanib reduces fluorescein leakage in idiopathic parafoveal telangiectasisCan J Ophthalmol200843449249318711476
PubMed Web of Science ®Google Scholar
Charbel IssaPFingerRPKruseKBaumüllerSSchollHPHolzFGMonthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective studyAm J Ophthalmol2011151587688621334595
PubMed Web of Science ®Google Scholar
ToyBCKooECukrasCMeyerleCBChewEYWongWTTreatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trialRetina2012325996100622266930
PubMed Web of Science ®Google Scholar
LiraRPSilvaVBCavalcantiTMde SouzaACPintoAPIntravitreous ranibizumab as treatment for macular telangiectasia type 2Arch Ophthalmol201012881075107820697014
PubMedGoogle Scholar
GassJDBlodiBAIdiopathic juxtafoveolar retinal telangiectasis: update of classification and follow-up studyOphthalmology199310010153615468414413
PubMed Web of Science ®Google Scholar
MylonasGAhlersCMalamosPComparison of retinal thickness measurements and segmentation performance of four different spectral and time domain OCT devices in neovascular age-related macular degenerationBr J Ophthalmol200993111453146019520692
PubMed Web of Science ®Google Scholar
GreenWRQuigleyHADe la CruzZCohenBParafoveal retinal telangiectasis: light and electron microscopy studiesTrans Ophthalmol Soc UK1980100Pt 11621706943823
PubMedGoogle Scholar
SanchezJGGarciaRAWuLOptical coherence tomography characteristics of group 2A idiopathic parafoveal telangiectasiasRetina20072791214122018046227
PubMed Web of Science ®Google Scholar
GuptaVGuptaADograMRAgarwalAOptical coherence tomography in group 2A idiopathic juxtafoveolar telangiectasisOphthalmic Surg Lasers Imaging200536648248616355952
PubMedGoogle Scholar
GaudricADucos de LahitteGCohenSYMassinPHaouchineBOptical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasisArch Ophthalmol2006124101410141917030708
PubMedGoogle Scholar
Charbel IssaPHolzFGSchollHPFindings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasiaOphthalmology200711491736174217822979
PubMed Web of Science ®Google Scholar
WilsonCABerkowitzBASatoYAndoNHandaJTde JuanEJrTreatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulationArch Ophthalmol19921108115511591497531
PubMedGoogle Scholar
MartinezJAIntravitreal triamcinolone acetonide for bilateral acquired parafoveal telangiectasisArch Ophthalmol2003121111658165914609935
PubMedGoogle Scholar
AlldredgeCDGarretsonBRIntravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasisRetina200323111311612652245
PubMed Web of Science ®Google Scholar
NishijimaKNgYSZhongLVascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injuryAm J Pathol20071711536717591953
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Twelve months of follow-up after intravitreal injection of ranibizumab for the treatment of idiopathic parafoveal telangiectasia

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date